Literature DB >> 16443735

Caspase activity is downregulated in choriocarcinoma: a cDNA array differential expression study.

P-Y Fong1, W-C Xue, H Y S Ngan, P-M Chiu, K Y K Chan, S W Tsao, A N Y Cheung.   

Abstract

BACKGROUND: Placental trophoblast can be considered to be pseudomalignant tissue and the pathogenesis of gestational trophoblastic diseases remains to be clarified. AIMS: To examine the role of caspases 8 and 10, identified by differential expression, on trophoblast tumorigenesis.
METHODS: cDNA array hybridisation was used to compare gene expression profiles in choriocarcinoma cell lines (JAR, JEG, and BeWo) and normal first trimester human placentas, followed by confirmation with quantitative real time polymerase chain reaction and immunohistochemistry. Caspase 10 and its closely related family member caspase 8 were analysed.
RESULTS: Downregulation of caspase 10 in choriocarcinoma was detected by both Atlastrade mark human cDNA expression array and Atlastrade mark human 1.2 array. Caspase 10 mRNA expression was significantly lower in hydatidiform mole (p = 0.035) and chorioarcinoma (p = 0.002) compared with normal placenta. The caspase 8 and 10 proteins were expressed predominantly in the cytotrophoblast and syncytiotrophoblast, respectively, with significantly lower expression in choriocarcinomas than other trophoblastic tissues (p < 0.05). Immunoreactivity for both caspase 8 and 10 correlated with the apoptotic index previously assessed by terminal deoxynucleotidyl transferase mediated dUTP nick end labelling (p = 0.02 and p = 0.04, respectively) and M30 (p < 0.001 and p = 0.003, respectively) approaches.
CONCLUSIONS: These results suggest that the downregulation of capases 8 and 10 might contribute to the pathogenesis of choriocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443735      PMCID: PMC1860314          DOI: 10.1136/jcp.2005.028027

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  33 in total

1.  Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody.

Authors:  P M Chiu; Y S Ngan; U S Khoo; A N Cheung
Journal:  Histopathology       Date:  2001-03       Impact factor: 5.087

2.  Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: correlation with mdm2, proliferation index, and clinicopathologic parameters.

Authors:  A. N. Y. Cheung; D. H. Shen; U. S. Khoo; M. P. M. Chiu; V. P. C. Tin; L. P. Chung; H. Y. S. Ngan
Journal:  Int J Gynecol Cancer       Date:  1999-03       Impact factor: 3.437

3.  Telomerase activity in gestational trophoblastic disease.

Authors:  A N Cheung; D K Zhang; Y Liu; H Y Ngan; D H Shen; S W Tsao
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

4.  Apoptosis in gestational trophoblastic disease is correlated with clinical outcome and Bcl-2 expression but not Bax expression.

Authors:  S Y Wong; H Y Ngan; C C Chan; A N Cheung
Journal:  Mod Pathol       Date:  1999-11       Impact factor: 7.842

5.  Molecular cloning and characterization of two novel pro-apoptotic isoforms of caspase-10.

Authors:  P W Ng; A G Porter; R U Jänicke
Journal:  J Biol Chem       Date:  1999-04-09       Impact factor: 5.157

6.  Methotrexate infusion in low-risk gestational trophoblastic disease.

Authors:  L C Wong; H Y Ngan; D K Cheng; T Y Ng
Journal:  Am J Obstet Gynecol       Date:  2000-12       Impact factor: 8.661

7.  Differential gene expression pattern between normal human trophoblast and choriocarcinoma cell lines: downregulation of heat shock protein-27 in choriocarcinoma in vitro and in vivo.

Authors:  G L Vegh; V Fulop; Y Liu; S W Ng; Z S Tuncer; D R Genest; P Paldi-Haris; J Foldi; S C Mok; R S Berkowitz
Journal:  Gynecol Oncol       Date:  1999-12       Impact factor: 5.482

8.  Syncytial fusion of human trophoblast depends on caspase 8.

Authors:  S Black; M Kadyrov; P Kaufmann; B Ugele; N Emans; B Huppertz
Journal:  Cell Death Differ       Date:  2004-01       Impact factor: 15.828

9.  Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta.

Authors:  B Huppertz; H G Frank; J C Kingdom; F Reister; P Kaufmann
Journal:  Histochem Cell Biol       Date:  1998-11       Impact factor: 4.304

10.  Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR.

Authors:  R R Adler; A K Ng; N S Rote
Journal:  Biol Reprod       Date:  1995-10       Impact factor: 4.285

View more
  6 in total

1.  Downregulation of caspase-10 predicting poor survival after resection of stage II colorectal cancer.

Authors:  Xiao-Gang Shen; Cun Wang; Yuan Li; Bin Zhou; Bin Xu; Lie Yang; Zong-Guang Zhou; Xiao-Feng Sun
Journal:  Int J Colorectal Dis       Date:  2011-05-11       Impact factor: 2.571

2.  Trophoblastic neoplasms express fatty acid synthase, which may be a therapeutic target via its inhibitor C93.

Authors:  Stefanie M Ueda; Tsui-Lien Mao; Francis P Kuhajda; Chanont Vasoontara; Robert L Giuntoli; Robert E Bristow; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

3.  Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR.

Authors:  Wing Pui Tsang; Timothy W L Wong; Albert H H Cheung; Chloe N N Co; Tim Tak Kwok
Journal:  RNA       Date:  2007-04-06       Impact factor: 4.942

4.  Functional comparison of innate immune signaling pathways in primates.

Authors:  Luis B Barreiro; John C Marioni; Ran Blekhman; Matthew Stephens; Yoav Gilad
Journal:  PLoS Genet       Date:  2010-12-16       Impact factor: 5.917

Review 5.  Apoptosis in cancer: from pathogenesis to treatment.

Authors:  Rebecca S Y Wong
Journal:  J Exp Clin Cancer Res       Date:  2011-09-26

Review 6.  The Modulation of Apoptotic Pathways by Gammaherpesviruses.

Authors:  Shuvomoy Banerjee; Timsy Uppal; Roxanne Strahan; Prerna Dabral; Subhash C Verma
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.